



## DEPARTMENT OF HEALTH

Wes Moore, Governor · Aruna Miller, Lt. Governor · Meena Seshamani, M.D., Ph.D., Secretary

### **Managed Care Organization Billing Guidance Cell and Gene Therapy Access Model Medications**

Providers will submit their claim for the Cell and Gene Therapy (CGT) medications, CASGEVY or LYFGENIA, related to the CGT Access Model (Model) on a UB04 claim. The Model requires the reimbursement of the approved medication to be at no less than actual acquisition cost. The provider may submit for the medication and infusion inpatient stay on the same claim.

An additional condition of payment for the CGT Model medications is ensuring that the authorized/qualified treatment center is a member of the Center for International Blood & Marrow Transplant Research (CIBMTR) registry and the provider participates in the CMS-directed study for the CGT Model gene therapies. More information is available [here](#).

*Note: Both Children's National Medical Center and University of Maryland Medical Center are CIBMTR participating centers. Providers may not use 340B discounts on any CGT Model Medications. At this time, Maryland Medicaid Fee-for-Service and the HealthChoice managed care organizations are not allowing any specialty pharmacies to submit claims for these medications.*